Meta's Aggressive AI Spending, Eli Lilly's Drug Trial, Qualcomm Earnings, and Comcast Subscribers

Meta's AI Investment Strategy

• 🚀 Meta Platforms is significantly increasing its spending in the artificial intelligence race, viewing it as a critical investment opportunity.
• 💡 While not selling AI models directly like competitors, Meta has been developing AI for a decade, primarily for internal use in ad targeting and content recommendations.
• 📈 The company's stock has performed exceptionally well, becoming the second-best performing stock in the MAG 7 year-to-date, driven by a strong ads business and Zuckerberg's leadership.
• 🎯 Meta leverages its vast existing user base across Facebook, Instagram, and WhatsApp to deploy its AI products, such as the Meta AI chatbot, giving it a built-in audience.
• 💰 Monetization of WhatsApp is beginning with ads, though significant revenue impact is not expected for several years due to user demographics and the need to shift advertiser budgets.
• ⚠️ Potential overhangs for Meta include the high level of spending and any potential stumble in the ads business, as well as continued losses in its Reality Labs division (Quest VR headsets).

Eli Lilly's Diabetes and Obesity Drug Performance

• 🔬 Eli Lilly's blockbuster drug, Mounjaro (also known as Zepbound for obesity), showed non-inferiority in a trial for preventing heart attacks and strokes compared to its older drug Trulicity, but did not prove superiority.
• 📈 Mounjaro/Zepbound is a major growth driver for Eli Lilly, with its cardio-metabolic health segment experiencing explosive revenue growth, projected to reach $52 billion next year.
• 💊 The company is also developing an oral GLP-1 pill, expected to democratize the market by appealing to individuals who prefer not to use injectables and may not need significant weight loss.
• 🏆 Eli Lilly is outpacing competitors like Novo Nordisk in the GLP-1 market and is on track to become the world's most valuable drug company, with significant investment in cancer and Alzheimer's research as well.
• 📊 Eli Lilly's stock trades at a significantly higher valuation (34 times 2025 earnings) compared to its peers (15 times), reflecting strong market confidence.

Qualcomm's Semiconductor Earnings and Outlook

• 📊 Qualcomm reported earnings with some positives, including beats in IoT due to smart glass chip sales to Meta and continued strength in its auto segment.
• 📉 However, the company faces significant headwinds from Apple's share loss starting next quarter, which is expected to weigh on revenue, with diversification efforts in IoT and auto not yet sufficient to fully offset this.
• 🚗 While Qualcomm has made progress in diversifying into automotive and IoT, the pace is slow, making it difficult to excite investors in the current market focused on fast-growing AI chip names.
• ⚠️ Tariffs are not being directly called out as a major impact by most semiconductor companies, including Qualcomm, though there may have been some initial pull-ins due to tariff fears that have since normalized.

Comcast's Subscriber Losses and Broadband Competition

• 📉 Comcast reported losing fewer broadband subscribers than feared, leading to a relief rally, despite experiencing its largest-ever broadband subscriber loss.
• 🌐 The broadband market is intensely competitive, with telecoms aggressively offering fixed wireless (5G home internet) and fiber options, attacking cable from both the low-end pricing and superior speed perspectives.
• 📺 Comcast is spinning off its challenged cable networks business into a company called Versent, leaving broadcast, Peacock streaming, theme parks, and studios as its core NBC Universal assets.
• 📈 While cable contributes the majority of Comcast's EBITDA, the company is focusing on promotions and pricing strategies to curb churn and defend its market share amidst ongoing intense competition from fiber and wireless providers.